Exploration of predictive biomarkers for postoperative recurrence of stage II/III colorectal cancer using genomic sequencing

Postoperative recurrence of colorectal cancer (CRC) eventually leads to therapeutic failure; therefore, treatment strategies based on accurate prediction of recurrence are urgently required. To identify biomarkers that can predict treatment outcomes, we compared the mutational profiles of surgically...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2022-09, Vol.11 (18), p.3457-3470
Main Authors: Kishigami, Fumishi, Tanaka, Yosuke, Yamamoto, Yoko, Ueno, Toshihide, Kojima, Shinya, Sato, Kazuhito, Inoue, Satoshi, Sugaya, Saori, Ishihara, Soichiro, Mano, Hiroyuki, Kawazu, Masahito
Format: Article
Language:English
Subjects:
Antigens
Automation
Biomarkers
Cancer
Chemotherapy
Cloning
Colorectal cancer
Colorectal carcinoma
Genes
Genomes
Genomic analysis
Mutation
Patients
Precision medicine
Survival analysis
Tumors
whole genome sequence
ZFP36L2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5200-424b6e061d47a7e4f72217acc81e51e831dc723b3069e6f591e99839861954673
cites cdi_FETCH-LOGICAL-c5200-424b6e061d47a7e4f72217acc81e51e831dc723b3069e6f591e99839861954673
container_end_page 3470
container_issue 18
container_start_page 3457
container_title Cancer medicine (Malden, MA)
container_volume 11
creator Kishigami, Fumishi
Tanaka, Yosuke
Yamamoto, Yoko
Ueno, Toshihide
Kojima, Shinya
Sato, Kazuhito
Inoue, Satoshi
Sugaya, Saori
Ishihara, Soichiro
Mano, Hiroyuki
Kawazu, Masahito
description Postoperative recurrence of colorectal cancer (CRC) eventually leads to therapeutic failure; therefore, treatment strategies based on accurate prediction of recurrence are urgently required. To identify biomarkers that can predict treatment outcomes, we compared the mutational profiles of surgically resected specimens from patients with recurrent cancer with those from patients with non‐recurrent cancer. Target sequencing, whole‐exome sequencing (WES), or whole‐genome sequencing (WGS) was performed on 89 and 58 tumors from recurrent and non‐recurrent cases, respectively. WGS revealed the driver mutations that were not detected with target sequencing or WES, including the structural variations affecting ZFP36L2. Loss of function of ZFP36L2 was frequently observed in primary tumors from recurrent cases. Furthermore, the recurrence‐free survival of patients with loss of function of ZFP36L2 was significantly shorter relative to patients with no loss of ZFP36L2 function. In summary, the study demonstrated that detailed genomic analysis could help improve precision medicine for CRC. Loss of function of ZFP36L2 was frequently observed in recurrent colorectal cancers. Furthermore, the recurrence‐free survival of colorectal cancer patients with loss of function of ZFP36L2 was significantly shorter relative to patients with no loss of ZFP36L2 function.
doi_str_mv 10.1002/cam4.4710
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_70f8080c74f44ac7bc190ca96315738f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_70f8080c74f44ac7bc190ca96315738f</doaj_id><sourcerecordid>2644361722</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5200-424b6e061d47a7e4f72217acc81e51e831dc723b3069e6f591e99839861954673</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhqMKRKvSA3-gssQFDtv1V-z4WK0KRCri0p4tZzJZeUniYCdAJX48TrdUCAlfbI0fP57RWxRvGL1ilPItuEFeSc3oSXHGqSw3Wgn54q_zaXGR0oHmpSlXmr0qTkUppKCmPCt-3fyc-hDd7MNIQkemiK2H2X9H0vgwuPgVYyJdiGQKaQ4Trmi-jAhLjDgCrq_S7PZI6npb1zWBkIUIs-sJuAxEsiQ_7skexzB4IAm_LflhLr0uXnauT3jxtJ8X9x9u7nafNrdfPta769sNlJzSjeSyUUgVa6V2GmWnOWfaAVQMS4aVYC1oLhpBlUHVlYahMZUwlWKmlEqL86I-etvgDnaKPs_1YIPz9rEQ4t66OHvo0WraVbSioGUnpQPdADMUnFGClVpUXXa9O7qmGPIcabaDT4B970YMS7JcSSkUyy1m9O0_6CEsccyTWq5Zmf9RhmXq_ZGCGFKK2D03yKhdE7ZrwnZNOLOXT8alGbB9Jv_kmYHtEfjhe3z4v8nurj_LR-VvhTiuGg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2715808691</pqid></control><display><type>article</type><title>Exploration of predictive biomarkers for postoperative recurrence of stage II/III colorectal cancer using genomic sequencing</title><source>Publicly Available Content Database</source><source>Wiley Open Access</source><source>PubMed Central</source><creator>Kishigami, Fumishi ; Tanaka, Yosuke ; Yamamoto, Yoko ; Ueno, Toshihide ; Kojima, Shinya ; Sato, Kazuhito ; Inoue, Satoshi ; Sugaya, Saori ; Ishihara, Soichiro ; Mano, Hiroyuki ; Kawazu, Masahito</creator><creatorcontrib>Kishigami, Fumishi ; Tanaka, Yosuke ; Yamamoto, Yoko ; Ueno, Toshihide ; Kojima, Shinya ; Sato, Kazuhito ; Inoue, Satoshi ; Sugaya, Saori ; Ishihara, Soichiro ; Mano, Hiroyuki ; Kawazu, Masahito</creatorcontrib><description>Postoperative recurrence of colorectal cancer (CRC) eventually leads to therapeutic failure; therefore, treatment strategies based on accurate prediction of recurrence are urgently required. To identify biomarkers that can predict treatment outcomes, we compared the mutational profiles of surgically resected specimens from patients with recurrent cancer with those from patients with non‐recurrent cancer. Target sequencing, whole‐exome sequencing (WES), or whole‐genome sequencing (WGS) was performed on 89 and 58 tumors from recurrent and non‐recurrent cases, respectively. WGS revealed the driver mutations that were not detected with target sequencing or WES, including the structural variations affecting ZFP36L2. Loss of function of ZFP36L2 was frequently observed in primary tumors from recurrent cases. Furthermore, the recurrence‐free survival of patients with loss of function of ZFP36L2 was significantly shorter relative to patients with no loss of ZFP36L2 function. In summary, the study demonstrated that detailed genomic analysis could help improve precision medicine for CRC. Loss of function of ZFP36L2 was frequently observed in recurrent colorectal cancers. Furthermore, the recurrence‐free survival of colorectal cancer patients with loss of function of ZFP36L2 was significantly shorter relative to patients with no loss of ZFP36L2 function.</description><identifier>ISSN: 2045-7634</identifier><identifier>EISSN: 2045-7634</identifier><identifier>DOI: 10.1002/cam4.4710</identifier><identifier>PMID: 35343095</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Antigens ; Automation ; Biomarkers ; Cancer ; Chemotherapy ; Cloning ; Colorectal cancer ; Colorectal carcinoma ; Genes ; Genomes ; Genomic analysis ; Mutation ; Patients ; Precision medicine ; Survival analysis ; Tumors ; whole genome sequence ; ZFP36L2</subject><ispartof>Cancer medicine (Malden, MA), 2022-09, Vol.11 (18), p.3457-3470</ispartof><rights>2022 The Authors. published by John Wiley &amp; Sons Ltd.</rights><rights>2022 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</rights><rights>2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5200-424b6e061d47a7e4f72217acc81e51e831dc723b3069e6f591e99839861954673</citedby><cites>FETCH-LOGICAL-c5200-424b6e061d47a7e4f72217acc81e51e831dc723b3069e6f591e99839861954673</cites><orcidid>0000-0003-4645-0181 ; 0000-0003-4146-3629</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2715808691/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2715808691?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,11562,25753,27924,27925,37012,37013,44590,46052,46476,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35343095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kishigami, Fumishi</creatorcontrib><creatorcontrib>Tanaka, Yosuke</creatorcontrib><creatorcontrib>Yamamoto, Yoko</creatorcontrib><creatorcontrib>Ueno, Toshihide</creatorcontrib><creatorcontrib>Kojima, Shinya</creatorcontrib><creatorcontrib>Sato, Kazuhito</creatorcontrib><creatorcontrib>Inoue, Satoshi</creatorcontrib><creatorcontrib>Sugaya, Saori</creatorcontrib><creatorcontrib>Ishihara, Soichiro</creatorcontrib><creatorcontrib>Mano, Hiroyuki</creatorcontrib><creatorcontrib>Kawazu, Masahito</creatorcontrib><title>Exploration of predictive biomarkers for postoperative recurrence of stage II/III colorectal cancer using genomic sequencing</title><title>Cancer medicine (Malden, MA)</title><addtitle>Cancer Med</addtitle><description>Postoperative recurrence of colorectal cancer (CRC) eventually leads to therapeutic failure; therefore, treatment strategies based on accurate prediction of recurrence are urgently required. To identify biomarkers that can predict treatment outcomes, we compared the mutational profiles of surgically resected specimens from patients with recurrent cancer with those from patients with non‐recurrent cancer. Target sequencing, whole‐exome sequencing (WES), or whole‐genome sequencing (WGS) was performed on 89 and 58 tumors from recurrent and non‐recurrent cases, respectively. WGS revealed the driver mutations that were not detected with target sequencing or WES, including the structural variations affecting ZFP36L2. Loss of function of ZFP36L2 was frequently observed in primary tumors from recurrent cases. Furthermore, the recurrence‐free survival of patients with loss of function of ZFP36L2 was significantly shorter relative to patients with no loss of ZFP36L2 function. In summary, the study demonstrated that detailed genomic analysis could help improve precision medicine for CRC. Loss of function of ZFP36L2 was frequently observed in recurrent colorectal cancers. Furthermore, the recurrence‐free survival of colorectal cancer patients with loss of function of ZFP36L2 was significantly shorter relative to patients with no loss of ZFP36L2 function.</description><subject>Antigens</subject><subject>Automation</subject><subject>Biomarkers</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Cloning</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Genes</subject><subject>Genomes</subject><subject>Genomic analysis</subject><subject>Mutation</subject><subject>Patients</subject><subject>Precision medicine</subject><subject>Survival analysis</subject><subject>Tumors</subject><subject>whole genome sequence</subject><subject>ZFP36L2</subject><issn>2045-7634</issn><issn>2045-7634</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kU1v1DAQhqMKRKvSA3-gssQFDtv1V-z4WK0KRCri0p4tZzJZeUniYCdAJX48TrdUCAlfbI0fP57RWxRvGL1ilPItuEFeSc3oSXHGqSw3Wgn54q_zaXGR0oHmpSlXmr0qTkUppKCmPCt-3fyc-hDd7MNIQkemiK2H2X9H0vgwuPgVYyJdiGQKaQ4Trmi-jAhLjDgCrq_S7PZI6npb1zWBkIUIs-sJuAxEsiQ_7skexzB4IAm_LflhLr0uXnauT3jxtJ8X9x9u7nafNrdfPta769sNlJzSjeSyUUgVa6V2GmWnOWfaAVQMS4aVYC1oLhpBlUHVlYahMZUwlWKmlEqL86I-etvgDnaKPs_1YIPz9rEQ4t66OHvo0WraVbSioGUnpQPdADMUnFGClVpUXXa9O7qmGPIcabaDT4B970YMS7JcSSkUyy1m9O0_6CEsccyTWq5Zmf9RhmXq_ZGCGFKK2D03yKhdE7ZrwnZNOLOXT8alGbB9Jv_kmYHtEfjhe3z4v8nurj_LR-VvhTiuGg</recordid><startdate>202209</startdate><enddate>202209</enddate><creator>Kishigami, Fumishi</creator><creator>Tanaka, Yosuke</creator><creator>Yamamoto, Yoko</creator><creator>Ueno, Toshihide</creator><creator>Kojima, Shinya</creator><creator>Sato, Kazuhito</creator><creator>Inoue, Satoshi</creator><creator>Sugaya, Saori</creator><creator>Ishihara, Soichiro</creator><creator>Mano, Hiroyuki</creator><creator>Kawazu, Masahito</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4645-0181</orcidid><orcidid>https://orcid.org/0000-0003-4146-3629</orcidid></search><sort><creationdate>202209</creationdate><title>Exploration of predictive biomarkers for postoperative recurrence of stage II/III colorectal cancer using genomic sequencing</title><author>Kishigami, Fumishi ; Tanaka, Yosuke ; Yamamoto, Yoko ; Ueno, Toshihide ; Kojima, Shinya ; Sato, Kazuhito ; Inoue, Satoshi ; Sugaya, Saori ; Ishihara, Soichiro ; Mano, Hiroyuki ; Kawazu, Masahito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5200-424b6e061d47a7e4f72217acc81e51e831dc723b3069e6f591e99839861954673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens</topic><topic>Automation</topic><topic>Biomarkers</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Cloning</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Genes</topic><topic>Genomes</topic><topic>Genomic analysis</topic><topic>Mutation</topic><topic>Patients</topic><topic>Precision medicine</topic><topic>Survival analysis</topic><topic>Tumors</topic><topic>whole genome sequence</topic><topic>ZFP36L2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kishigami, Fumishi</creatorcontrib><creatorcontrib>Tanaka, Yosuke</creatorcontrib><creatorcontrib>Yamamoto, Yoko</creatorcontrib><creatorcontrib>Ueno, Toshihide</creatorcontrib><creatorcontrib>Kojima, Shinya</creatorcontrib><creatorcontrib>Sato, Kazuhito</creatorcontrib><creatorcontrib>Inoue, Satoshi</creatorcontrib><creatorcontrib>Sugaya, Saori</creatorcontrib><creatorcontrib>Ishihara, Soichiro</creatorcontrib><creatorcontrib>Mano, Hiroyuki</creatorcontrib><creatorcontrib>Kawazu, Masahito</creatorcontrib><collection>Wiley Open Access</collection><collection>Wiley Free Archive</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cancer medicine (Malden, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kishigami, Fumishi</au><au>Tanaka, Yosuke</au><au>Yamamoto, Yoko</au><au>Ueno, Toshihide</au><au>Kojima, Shinya</au><au>Sato, Kazuhito</au><au>Inoue, Satoshi</au><au>Sugaya, Saori</au><au>Ishihara, Soichiro</au><au>Mano, Hiroyuki</au><au>Kawazu, Masahito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exploration of predictive biomarkers for postoperative recurrence of stage II/III colorectal cancer using genomic sequencing</atitle><jtitle>Cancer medicine (Malden, MA)</jtitle><addtitle>Cancer Med</addtitle><date>2022-09</date><risdate>2022</risdate><volume>11</volume><issue>18</issue><spage>3457</spage><epage>3470</epage><pages>3457-3470</pages><issn>2045-7634</issn><eissn>2045-7634</eissn><abstract>Postoperative recurrence of colorectal cancer (CRC) eventually leads to therapeutic failure; therefore, treatment strategies based on accurate prediction of recurrence are urgently required. To identify biomarkers that can predict treatment outcomes, we compared the mutational profiles of surgically resected specimens from patients with recurrent cancer with those from patients with non‐recurrent cancer. Target sequencing, whole‐exome sequencing (WES), or whole‐genome sequencing (WGS) was performed on 89 and 58 tumors from recurrent and non‐recurrent cases, respectively. WGS revealed the driver mutations that were not detected with target sequencing or WES, including the structural variations affecting ZFP36L2. Loss of function of ZFP36L2 was frequently observed in primary tumors from recurrent cases. Furthermore, the recurrence‐free survival of patients with loss of function of ZFP36L2 was significantly shorter relative to patients with no loss of ZFP36L2 function. In summary, the study demonstrated that detailed genomic analysis could help improve precision medicine for CRC. Loss of function of ZFP36L2 was frequently observed in recurrent colorectal cancers. Furthermore, the recurrence‐free survival of colorectal cancer patients with loss of function of ZFP36L2 was significantly shorter relative to patients with no loss of ZFP36L2 function.</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>35343095</pmid><doi>10.1002/cam4.4710</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-4645-0181</orcidid><orcidid>https://orcid.org/0000-0003-4146-3629</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-7634
ispartof Cancer medicine (Malden, MA), 2022-09, Vol.11 (18), p.3457-3470
issn 2045-7634
2045-7634
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_70f8080c74f44ac7bc190ca96315738f
source Publicly Available Content Database; Wiley Open Access; PubMed Central
subjects Antigens
Automation
Biomarkers
Cancer
Chemotherapy
Cloning
Colorectal cancer
Colorectal carcinoma
Genes
Genomes
Genomic analysis
Mutation
Patients
Precision medicine
Survival analysis
Tumors
whole genome sequence
ZFP36L2
title Exploration of predictive biomarkers for postoperative recurrence of stage II/III colorectal cancer using genomic sequencing
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A16%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exploration%20of%20predictive%20biomarkers%20for%20postoperative%20recurrence%20of%20stage%20II/III%20colorectal%20cancer%20using%20genomic%20sequencing&rft.jtitle=Cancer%20medicine%20(Malden,%20MA)&rft.au=Kishigami,%20Fumishi&rft.date=2022-09&rft.volume=11&rft.issue=18&rft.spage=3457&rft.epage=3470&rft.pages=3457-3470&rft.issn=2045-7634&rft.eissn=2045-7634&rft_id=info:doi/10.1002/cam4.4710&rft_dat=%3Cproquest_doaj_%3E2644361722%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5200-424b6e061d47a7e4f72217acc81e51e831dc723b3069e6f591e99839861954673%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2715808691&rft_id=info:pmid/35343095&rfr_iscdi=true